New patient intro: $89 first month, then $199/month. Cancel anytime.
The Aurelius Journal
Every compound in our protocols has a paper trail. These articles walk through the actual studies, rate the evidence honestly, and flag where the data is still being worked out. No cherry picked abstracts. No marketing language.
Who qualifies for tirzepatide? The BMI 30 and 27 thresholds, the conditions that count, the diabetes and sleep apnea routes, and who should not take it.

All Articles

Does tirzepatide help asthma? What weight loss trials, 2026 records studies and a respiratory safety review show, and what has not been tested yet.

Mounjaro and Zepbound are the same drug in the same doses. What differs is the FDA label, how the dose is chosen, the trial evidence and insurance coverage.

Fatigue was reported by 5% to 7% of people on tirzepatide versus 3% on placebo. Why it happens, how compounded and low dose use fit in, and when to call.

What tirzepatide is made of: the 39 amino acid peptide, its C20 fatty acid chain, the inactive ingredients in the pen, and how compounded versions differ.

How microdosing tirzepatide works: what low doses do in the body, what the 1 mg trial arm showed, and what is known about inflammation and pancreatitis.

Zepbound vs Wegovy: what SURMOUNT-5 found, which uses each label covers, how dosing differs and what each costs without insurance.

Is GLP-1 for PCOS covered by insurance? Rarely for PCOS itself. Coverage follows a weight, diabetes or sleep apnea indication. Here is how plans decide.

Can low dose tirzepatide cause hair loss? The label's dose by dose numbers, why weight loss is the likely trigger, and what is unknown about microdosing.

SURMOUNT-3 tested a 12 week diet and activity program before tirzepatide. What the trial found, what it cannot tell us, and how it applies to real patients.

In SURMOUNT-1, far fewer people with prediabetes developed type 2 diabetes on tirzepatide than on placebo. What the data show, and what happened after stopping.

Many people on tirzepatide report quieter binge urges. What early studies show, how GLP-1 and GIP signaling may affect food reward, the risks, and the trial underway.

Tirzepatide's weight loss now approaches some bariatric procedures. How the two compare on average results, durability after stopping, risks and who qualifies for each.

Tirzepatide can quiet hunger so much that some people eat far less than they need. The signs of underfueling, why it costs muscle, and sensible calorie and protein floors.

Eating less on tirzepatide can mean fewer vitamins too. What GLP-1 research shows about vitamin D, iron, B12 and thiamine, and which labs are worth discussing.

Tirzepatide trims fat fast, but some lean mass goes too. What the research says about adding creatine, typical dosing, water weight and the kidney lab quirk.

Lipedema fat often resists diet and exercise. What early studies suggest about tirzepatide for lipedema, where the evidence stops, and how it fits with standard care.

Psoriasis travels with obesity. What the TOGETHER-PsO and TOGETHER-PsA trials found when tirzepatide was added to a biologic for skin and joint outcomes.

Visceral fat is the deep belly fat most tied to metabolic risk. What SURMOUNT-1 DXA and SURPASS-3 MRI scans showed on tirzepatide, and how to track waist size at home.

Over the counter glucose sensors are easy to buy. What CGM readings look like on tirzepatide, who benefits most from one, and how to read time in range.

Fear of weight gain keeps many people smoking. What GLP-1 research suggests about nicotine cravings, what tirzepatide trials are testing, and how to quit safely.

In the SUMMIT trial, tirzepatide was linked to fewer heart failure events and better symptoms in adults with HFpEF and obesity. What the data show and where the evidence stops.

Scale weight is noisy on tirzepatide. Why a 7 day average, waist size, blood pressure, A1C and body composition give a clearer read, and what SURMOUNT-1 showed.

Tirzepatide trial averages hide a wide range of results. What SURMOUNT data show about slower responders, the factors linked to smaller losses and what clinicians review.

Tirzepatide is not a known direct cause of kidney stones, but less thirst, GI fluid loss and very high protein eating can concentrate urine. Who is at risk and how to hydrate.

Restaurant portions were built for an appetite tirzepatide reduces. How to order, when in the weekly cycle a large meal is easiest, and which dishes reliably cause trouble.

One molecule, two incretin receptors. What GIP and GLP-1 each do in the pancreas, gut, fat and brain, why dual agonism beat semaglutide head to head, and how weekly dosing works.

No trial has tested keto on top of tirzepatide, and SURMOUNT used no carbohydrate rules at all. Where the two overlap, where strict keto stacks risk, and a sensible carb range.

Calorie burn falls on tirzepatide by about what a smaller body predicts, no more. What an 18 week metabolic chamber trial found, and the levers that protect metabolic rate.

Women lost more weight than men in all four SURMOUNT trials, and the gap widens after month 6. How large it is, why it likely happens, and what it means for each sex.

Appetite changes in one to two weeks, measurable loss in the first month, most of the result between months three and nine. The SURMOUNT timeline, stage by stage.

Flu shots and COVID boosters are not restricted on tirzepatide and no interaction is listed. How to time a vaccine around the weekly injection and tell overlapping side effects apart.

Coffee is not restricted with tirzepatide and the two have no known interaction. Why caffeine still feels stronger on GLP-1 therapy, and how to adjust the cup rather than give it up.

Dizziness on tirzepatide usually traces to blood pressure, fluid, fuel, or a mismatched diabetes drug. How to tell which one it is, and what resolves it without a dose change.

Belching was reported by roughly 5 to 6 percent of tirzepatide participants in SURMOUNT. Why the sulfur version happens, when it fades, and what reduces it.

Cold intolerance is not a listed tirzepatide side effect. Why losing weight changes how cold a room feels, and the lab results worth checking first.

Local reactions were reported by roughly 3 to 6 percent of participants in SURMOUNT-1, and most were mild. How to tell an ordinary reaction from one that needs review.

GLP-1 therapy changes gut transit, food volume, and fiber intake at once, and the microbiome responds to all three. What the evidence supports, and what is still speculation.

Tirzepatide slows gastric emptying and drives weight loss, and both change how other medications behave. The interactions and dose reviews worth planning first.

Dry mouth, acid exposure, and a changed eating pattern alter conditions inside the mouth on tirzepatide. What saliva does, and how to protect enamel without stopping treatment.

Intermittent fasting and tirzepatide both reduce energy intake, so stacking them deepens the deficit rather than adding a second mechanism. What that costs in lean mass.

Menstrual changes on tirzepatide trace back to fat loss, insulin sensitivity, and energy availability rather than the drug itself. Which shifts to track and which to have evaluated.

Altered taste on tirzepatide covers three separate changes: distorted flavour, learned food aversion, and reduced reward. What the evidence shows and how to protect protein.

Tirzepatide carries no ban on alcohol, but it changes the context around every drink. What the evidence suggests about blood sugar, the pancreas, and tolerance.

Diarrhea was reported by 18.7 to 23.0 percent of tirzepatide participants in SURMOUNT-1 against 7.3 percent on placebo. What drives it, and what actually helps.

Pooled data reports 13.6 to 15.5 percent weight loss with tirzepatide after bariatric surgery, while conversion to a gastric bypass reported roughly double over three years.

Tirzepatide reduced serum uric acid by up to 0.95 mg/dL in SURMOUNT-1, yet gout flares can appear early. Why urate rises before it falls, and when the risk window is.

What the SURPASS-CVOT retinopathy substudy found, why early blurred vision happens, and how ophthalmology groups assess the NAION signal across GLP-1 medications.

Tirzepatide raises resting heart rate by roughly 2 to 4 bpm. What the SURMOUNT-1 monitoring substudy measured, the mechanism, and when a pulse change matters.

Slowed gastric emptying is how tirzepatide works, not a malfunction. What the cohort data actually show, why symptoms mislead, and what changed for procedures.

SURMOUNT-5 and SURPASS-2 compared the two directly, and both favored tirzepatide. Where the numbers stop deciding, and what semaglutide is still approved for.

Headache is reported by roughly 4% to 14% of people on tirzepatide. The four pathways behind it, how to tell them apart, and what actually resolves each one.

Tirzepatide's long half life gives a late injection a built in margin. What the 4 day rule means, why doubling up backfires, and when a longer gap needs a prescriber.

Antidepressant associated weight gain varies enormously by drug and builds over years. What the evidence shows, and where GLP-1 therapy does and does not fit.

Loose skin after tirzepatide is a mechanical result of lost volume, not a drug side effect. What predicts how much appears, why the rate of loss matters, and what evidence supports.

Tirzepatide rarely drives glucose low on its own because its insulin effect is glucose dependent. What changes the picture is almost always another agent in the regimen.

The reduction phase runs about a year and maintenance runs indefinitely. What the SURMOUNT-4 withdrawal data showed, and whether the dose can come down.

The trials enrolled adults into their seventies and the metabolic effects held. What changes after 60 is muscle reserve, bone reserve, and the medication list.

The starting dose is labeled for initiation rather than glycemic control. What each step is for, where the SURMOUNT dose response curve bends, and why four weeks.

Pancreatitis appears in the prescribing information for every GLP-1 medication and is genuinely uncommon. What the evidence shows, and which pain pattern warrants same day evaluation.

Fluid intake declines through arithmetic rather than symptoms. Where the water goes, what the label says about volume depletion, and what a sick day plan contains.

Slower gastric emptying is central to how tirzepatide works and is also why reflux appears. What the cohort data shows, when symptoms peak, and the measures that help.

A once weekly injection does not produce a once weekly effect. How the five day half life, time to peak, and steady state explain the day to day variation.

Weight is the most visible marker on tirzepatide and the least informative alone. Which labs move, when each becomes interpretable, and what a baseline panel covers.

The boxed warning describes thyroid tumors seen in rodents. What it means, who is contraindicated, and why levothyroxine requirements shift during weight loss.

Tirzepatide carries a labeled interaction with oral contraceptives during dose escalation. Why it happens, what the label advises, and why ovulation can return.

GLP-1 medications slow gastric emptying, which matters before anesthesia. How the guidance changed, what elevated risk means, and what to disclose.

The three approved injection sites, step by step technique, needle angle, and why site rotation protects both comfort and how well the medication absorbs.

Constipation on tirzepatide comes from slowed gut motility plus less food, fiber, and fluid. Here is why it happens and the levers that keep the gut moving.

Tirzepatide tolerates room temperature for a defined window, clears airport security like insulin, and adapts to time zones. Here is how to keep a protocol on track while away.

Rapid weight loss raises gallstone risk, and tirzepatide produces rapid weight loss. Here is what changes in the biliary system and the levers that lower the odds.

Nausea on tirzepatide comes from delayed gastric emptying and central appetite signaling, not an irritated stomach. Here is why it happens and the levers that reduce it.

Ozempic face is facial volume loss and skin laxity from rapid weight loss, not a drug effect. Here is why it happens and how a controlled pace and skin care soften it.

Increased hair shedding during GLP-1 weight loss is a temporary, reversible reaction called telogen effluvium. Here is why it happens and how to support regrowth.

Weight loss stalls on tirzepatide are common, predictable, and usually temporary. Here is why the scale stops moving and the evidence based levers that restart progress.

Rapid weight loss on tirzepatide can lower bone mineral density at the hip and femoral neck. The effect tracks with weight lost and is largely modifiable.

When semaglutide or tirzepatide is stopped, published trials show most lost weight returns within a year. What the STEP and SURMOUNT withdrawal data reveal, and why.

Transdermal estrogen bypasses the gut and liver, which changes how it fits with GLP-1. What current menopause guidance says about delivery route and body composition.

A 2025 Mayo Clinic analysis found HRT combined with tirzepatide produced 17% weight loss versus 14% on tirzepatide alone. What that means for women on estrogen therapy who are still stuck.

Energy on tirzepatide follows two phases: an early titration dip with fixable causes, then a sustained recovery that often exceeds pre treatment baseline.

Patient reported quality of life improves substantially on tirzepatide across physical function, mood, sleep, and social life. Here are 10 reasons it rivals the labs.

Weight related joint pain often eases on tirzepatide within 3 to 6 months, before the full weight loss accrues. Here are 10 reasons the joints improve faster than the scale.

CRP drops 20 to 40 percent on tirzepatide and IL-6 follows. Here are 10 reasons the anti-inflammatory effect may underlie most of the medication's other benefits.

Tirzepatide cuts albuminuria 30 to 50 percent and slows eGFR decline in type 2 diabetes. Here are 10 reasons the kidney protection signal deserves more attention.

Most users say the constant background thinking about food goes quiet on tirzepatide. Here are 10 reasons the food noise reduction may be its most underrated effect.

Tirzepatide cuts liver fat 40 to 60 percent and improves fibrosis biomarkers in MASLD and MASH. Here are 10 reasons the quiet liver result matters.

Zepbound became the first medication ever FDA approved for moderate to severe OSA in adults with obesity. Here are 10 reasons the SURMOUNT-OSA result changed treatment.

Tirzepatide drops triglycerides 15 to 30 percent, far more than its modest LDL effect. Here are 10 reasons the lipid changes matter for metabolic syndrome.

Tirzepatide averaged 20 to 22 percent bodyweight loss in SURMOUNT, but the composition underneath the scale, visceral fat and lean mass, decides whether it lasts.

Tirzepatide lowered HbA1c 1.9 to 2.6 points in the SURPASS trials, the largest drops ever for a non insulin medication. Here are 10 reasons the magnitude matters.

PCOS is a metabolic disorder of insulin resistance before it is a reproductive one. Here are 10 reasons tirzepatide targets the upstream driver, and the evidence limits.

On tirzepatide the drug already creates the deficit, so the gym's real job is protecting muscle. Here are 10 reasons lifting heavy beats cardio on a GLP-1.

Tirzepatide suppresses appetite and slows gastric emptying, which makes protein and micronutrients harder to hit. Here are 10 foods that protect lean mass and energy.

Systolic BP drops 6 to 10 mmHg on tirzepatide — more than weight loss alone explains. Here are 10 reasons the BP reduction matters clinically.

Blood pressure, triglycerides, visceral fat, and HbA1c all improve measurably on tirzepatide. Here are 10 cardiovascular benefits backed by the trial data.

Why a gentler GLP-1 approach may be the smartest first step for women navigating perimenopause, hormonal shifts, and menopausal metabolic change.

Published clinical data on tolerability, adherence, lean mass preservation, and why physician-supervised microdose protocols reduce long-term risk.

Dopamine, BDNF, neuroinflammation, slow-wave sleep — a clinician's breakdown of what microdose GLP-1 does to the nervous system across 9 brain regions.

Ten reasons patients are switching from full-dose Ozempic to microdose GLP-1 protocols, from nausea and muscle loss to rebound weight gain.

The DPP showed 58 percent T2D risk reduction from 7 percent weight loss. A 12-month protocol combining lifestyle and, for eligible men, GLP-1 to normalize A1C sustainably.

An A1C between 5.7 and 6.4 percent is a ten year fork. Here is what the DPP data, ADA guidance, and GLP-1 trials actually show about moving the number.

The SELECT trial showed semaglutide reduced cardiovascular events by 20% in post-cardiac patients with obesity. What that means for cardiac rehab graduates and how a protocol works.

TRT restores testosterone but rarely drives meaningful fat loss alone. The mechanism behind stubborn midsection fat on TRT and what adding GLP-1 actually changes.

Pregabalin drives weight gain in 11.4% of users via appetite increase and edema. The mechanism, the tradeoffs, and what works when the neuropathy medication cannot be stopped.

After BSO, weight accumulates up to 3x faster than natural menopause. The biology of abrupt estrogen loss, visceral fat preference, and what a weight protocol for this population should address.

Metoprolol can drive 2 to 5 kg per year of weight gain in roughly 26 percent of long term users. The mechanism, the trade offs, and a coordinated weight plan that runs alongside cardiac protection.

Beta blockers and GLP-1 medications can be taken together with specific coordination. The interaction profile, bradycardia and hypoglycemia risks, and how providers structure the protocol.

Microdosing and standard dosing are different tools built around different goals. The evidence base is younger for microdosing but the clinical logic is coherent.

Three April 2026 studies on GLP-1 resistance, genetic side effect predictors, and benefits beyond weight loss are reshaping how clinicians think about protocols.

A 2026 meta-analysis confirms GLP-1 receptor agonists significantly raise testosterone in men. Here is what the data shows and why the optimization community is paying attention.

GLP-1 receptors in the dorsomedial hypothalamus directly regulate circadian biology. Here is what the research shows about sleep quality, beyond the sleep apnea headlines.

At full therapeutic doses, 25–40% of weight lost on GLP-1s can come from lean tissue. Here is the evidence based protocol for lean mass preservation.

The SELECT trial found a 20% reduction in cardiovascular events on semaglutide, partially independent of weight loss. Here is what the cardiac mechanism means for non-obese users.

GLP-1 receptors in the brain's reward circuit directly modulate dopamine signaling. Here is the neuroscience behind why alcohol cravings change on a GLP-1 protocol.

Brain fog is not vague — it has a documented biology. Here is what GLP-1 receptors in the hippocampus and cortex do to neuroinflammation, insulin signaling, and cognitive function.

Normal A1C does not mean optimal metabolism. Here is what GLP-1 receptor activation does to insulin sensitivity and glucose variability in people without diabetes.

Researchers are now calling GLP-1s the first longevity drugs. Here is what the science actually shows about aging, healthspan, and why the biohacking community is paying attention.

Injectable GLP-1 was built for clinical weight loss. Microdosed protocols use the same receptor mechanism at a fraction of the labeled dose. What the comparison actually turns on.

Full-dose GLP-1 protocols were designed for T2D. The metabolic levers they pull are real. The side effect profile at therapeutic doses is also real. Here's what changes at a fraction of that dose.

Perimenopause isn't primarily a weight problem. It's a metabolic, hormonal, and neurological shift. Here's how microdosed GLP-1 addresses the mechanisms behind energy crashes, brain fog, and sleep disruption.